Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14955970 | 0.84 | MGLL (0.34) | MGLL | |
| SCHEMBL1509231 | 0.81 | MGLL (0.31) | MGLL | |
| Hydrochloric Acid SCHEMBL1509240 | 0.80 | DPP4 (0.31) | MGLL | |
| SCHEMBL18359402 | 0.77 | HTR2C (0.34) | MGLL | |
| SCHEMBL2752939 | 0.76 | MAPT (0.36) | — | |
| SCHEMBL24656037 | 0.71 | GSK3B (0.32) | MGLLGSK3BDYRK1A | |
| SCHEMBL17611615 | 0.71 | MGLL (0.33) | MGLLGSK3BDYRK1A | |
| SCHEMBL929279 | 0.71 | POLB (0.47) | MGLLGSK3BDYRK1A | |
| SCHEMBL109874 | 0.71 | MGLL (0.33) | MGLLGSK3BDYRK1A | |
| SCHEMBL212149 | 0.70 | MGLL (0.36) | MGLLGSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-2647624-B1 | INTERMEDIATES OF SITAGLIPTIN AND PREPARATION PROCESS THEREOF | ZHEJIANG HISOAR PHARMACEUTICAL CO LTD (CN) | 2016-10-12 | — | — | EP | disclosed |
| US-9409912-B2 | Process for the preparation of sitagliptin phosphate | CADILA HEALTHCARE LIMITED (IN) | 2016-08-09 | — | — | US | disclosed |
| US-9233967-B2 | Process for the preparation of sitagliptin and intermediate compounds | CIPLA LIMITED (IN) | 2016-01-12 | — | — | US | disclosed |
| US-20150197523-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND INTERMEDIATE COMPOUNDS | CIPLA LIMITED (IN) | 2015-07-16 | — | — | US | disclosed |
| US-20150087834-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN PHOSPHATE | CADILA HEALTHCARE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-8624026-B2 | Method of preparing sitagliptin and intermediates used therein | HANMI SCIENCE CO., LTD (KR) | 2014-01-07 | — | — | US | disclosed |
| EP-2647624-A1 | INTERMEDIATES OF SITAGLIPTIN AND PREPARATION PROCESS THEREOF | Zhejiang Hisoar Pharmaceutical Co., Ltd (CN) | 2013-10-09 | — | — | EP | disclosed |
| WO-2013114173-A1 | A NOVEL PROCESS FOR THE PREPARATION OF SITAGLIPTIN | SMILAX LABORATORIES LIMITED (IN) | 2013-08-08 | — | — | WO | disclosed |
| US-20120214997-A1 | METHOD OF PREPARING SITAGLIPTIN AND INTERMEDIATES USED THEREIN | HANMI HOLDINGS CO., LTD. (KR) | 2012-08-23 | — | — | US | disclosed |
| EP-2334689-A2 | FUSED HETEROCYCLIC COMPOUND | LG Life Sciences Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
| US-7612072-B2 | Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor | MERCK & CO., INC. (US) | 2009-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214997-A1 | METHOD OF PREPARING SITAGLIPTIN AND INTERMEDIATES USED THEREIN | DPP4, DPP7, DPP8 | MGLL 938/4885LMNA 3306/4885GSK3B 316/4885 |
| US-20150087834-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN PHOSPHATE | DPP4, DPP9, SI | MGLL 1358/4885LMNA 4267/4885GSK3B 197/4885 |
| US-20150197523-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND INTERMEDIATE COMPOUNDS | DPP4, DPP7, DPP9 | MGLL 4063/4885LMNA 2767/4885GSK3B 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.